Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Laboratories & Research
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: TROV
- Previous Close: $2.10
- 50 Day Moving Average: $2.16
- 200 Day Moving Average: $3.49
- 52-Week Range: $1.77 - $6.93
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.02
- P/E Growth: 0.00
- Market Cap: $62.76M
- Outstanding Shares: 30,615,000
- Beta: 0.8
- Net Margins: -9,703.32%
- Return on Equity: -104.43%
- Return on Assets: -63.04%
Companies Related to TrovaGene:
- Debt-to-Equity Ratio: 0.58%
- Current Ratio: 7.31%
- Quick Ratio: 7.31%
What is TrovaGene's stock symbol?
TrovaGene trades on the NASDAQ under the ticker symbol "TROV."
Where is TrovaGene's stock going? Where will TrovaGene's stock price be in 2017?
8 equities research analysts have issued 1-year price objectives for TrovaGene's stock. Their predictions range from $4.00 to $9.00. On average, they expect TrovaGene's stock price to reach $6.75 in the next twelve months.
When will TrovaGene announce their earnings?
TrovaGene is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
What are analysts saying about TrovaGene stock?
Here are some recent quotes from research analysts about TrovaGene stock:
According to Zacks Investment Research, "Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. " (12/7/2016)
Cantor Fitzgerald analysts commented, "The partnership with Boreal Genomics is an important milestone for the company, in our view. Per the long-term supply and distribution agreement, 1) TROV commits upfront and milestone payments totaling $1M, 2) TROV has global distribution rights in blood and exclusively in urine for least ten years, and 3) TROV and Boreal will form a joint effort to bring the assay kits and systems through the necessary regulatory pathways for approval. Importantly, TROV continues to target the analytical validation of its initial panel by the end of 2016 and plans to launch a series of cancer-specific multigene ctDNA urine and blood panels, in partnership with Boreal, in 2017. For more details on TROV’s commercialization strategy, please see our September 30, 2016 note. The OnTarget platform separates target mutations from the wild-type. In a one-hour process, the sample is injected into a gel matrix containing short oligo probes that are complementary to the target mutations. The temperature is increased to the melting temperature of the target-probe duplex and target mutations are separated by repeated hybridization in an alternating electric field. Target alleles are collected in the extraction chamber, while the wild-type is removed with more than 1M fold enrichment (and as high as 10M fold)." (11/30/2016)
Maxim Group analysts commented, "Trovagene announced that the company has entered into an agreement with Multiplan, Inc." (3/1/2016)
Who owns TrovaGene stock?
TrovaGene's stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (1.41%). Company insiders that own TrovaGene stock include Antonius Schuh, Bridger Management, Llc, Mark Erlander, Stanley Tennant, Steve Zaniboni and William J Welch.
Who bought TrovaGene stock? Who is buying TrovaGene stock?
TrovaGene's stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp. Company insiders that have bought TrovaGene stock in the last two years include Antonius Schuh, Bridger Management, Llc, Mark Erlander, Stanley Tennant, Steve Zaniboni and William J Welch.
How do I buy TrovaGene stock?
Shares of TrovaGene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of TrovaGene stock cost?
One share of TrovaGene stock can currently be purchased for approximately $2.10.